📣 VC round data is live. Check it out!
- Public Comps
- ToolGen
ToolGen Valuation Multiples
Discover revenue and EBITDA valuation multiples for ToolGen and similar public comparables like Prenetics Global, SOPHiA Genetics, Atrys Health, Myriad Genetics and more.
ToolGen Overview
About ToolGen
ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
Founded
1999
HQ

Employees
22
Website
Financials (FY)
EV
$288M
Valuation Multiples
Start free trialToolGen Financials
ToolGen reported last fiscal year revenue of $867K and negative EBITDA of ($23M).
In the same fiscal year, ToolGen generated $756K in gross profit, ($23M) in EBITDA losses, and had net loss of ($24M).
ToolGen P&L
In the most recent fiscal year, ToolGen reported revenue of $867K and EBITDA of ($23M).
ToolGen is unprofitable as of last fiscal year, with gross margin of 87%, EBITDA margin of (2595%), and net margin of (2814%).
Financial data powered by Morningstar, Inc.
ToolGen Stock Performance
ToolGen has current market cap of $304M, and enterprise value of $288M.
Market Cap Evolution
ToolGen's stock price is $33.78.
ToolGen share price increased by 5.8% in the last 30 days, and by 72.0% in the last year.
ToolGen has an EPS (earnings per share) of $-2.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $288M | $304M | 5.8% | 5.8% | -7.4% | 72.0% | $-2.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialToolGen Valuation Multiples
ToolGen trades at 331.7x EV/Revenue multiple, and (12.8x) EV/EBITDA.
ToolGen Financial Valuation Multiples
As of June 3, 2026, ToolGen has market cap of $304M and EV of $288M.
ToolGen has a P/E ratio of (12.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ToolGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


ToolGen Margins & Growth Rates
In the most recent fiscal year, ToolGen reported gross margin of 87%, EBITDA margin of (2595%), and net margin of (2814%).
ToolGen Margins
ToolGen Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
ToolGen Operational KPIs
ToolGen's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
ToolGen Competitors
ToolGen competitors include Prenetics Global, SOPHiA Genetics, Atrys Health, Myriad Genetics, Korro Bio, Abclon, Mirxes Holding, Pacific Biosciences, Cibus and Atlantic International.
Most ToolGen public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.1x | 2.1x | (21.9x) | (18.5x) | |||
| 4.6x | 4.2x | (8.6x) | (9.4x) | |||
| 2.8x | 2.7x | 19.4x | 17.6x | |||
| 0.6x | 0.6x | 12.6x | 12.8x | |||
| 18.0x | 26.1x | (1.4x) | (1.1x) | |||
| 132.8x | - | (38.3x) | - | |||
| 19.4x | - | (5.6x) | - | |||
| 5.7x | 5.6x | (6.0x) | (6.6x) | |||
This data is available for Pro users. Sign up to see all ToolGen competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ToolGen
| When was ToolGen founded? | ToolGen was founded in 1999. |
| Where is ToolGen headquartered? | ToolGen is headquartered in South Korea. |
| How many employees does ToolGen have? | As of today, ToolGen has over 22 employees. |
| Is ToolGen publicly listed? | Yes, ToolGen is a public company listed on Korea Exchange. |
| What is the stock symbol of ToolGen? | ToolGen trades under 199800 ticker. |
| When did ToolGen go public? | ToolGen went public in 2014. |
| Who are competitors of ToolGen? | ToolGen main competitors include Prenetics Global, SOPHiA Genetics, Atrys Health, Myriad Genetics, Korro Bio, Abclon, Mirxes Holding, Pacific Biosciences, Cibus, Atlantic International. |
| What is the current market cap of ToolGen? | ToolGen's current market cap is $304M. |
| What is the current revenue of ToolGen? | ToolGen's last fiscal year revenue is $867K. |
| What is the current EV/Revenue multiple of ToolGen? | Current revenue multiple of ToolGen is 331.7x. |
| Is ToolGen profitable? | No, ToolGen is not profitable. |
| How many companies ToolGen has acquired to date? | ToolGen hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies ToolGen has invested to date? | ToolGen hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to ToolGen
Lists including ToolGen
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.